StockpollyBeta
Get App
Popularity #2,189
JANX · NASDAQ · Biotechnology

Janux Therapeutics (JANX)

Engineers antibodies that stay dormant until reaching a tumor, then engage T cells.

$16.82
vs last close−0.65 (−3.72%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue32190000108410
Cost of revenue111122125291900
Gross profit2218−2−21−25−299−1310
18182122348101645413742
Research & development121214151921253535322731
6677188101010111111
Selling & marketing00−1−100000000
General & administrative667818810100111111
Other expenses−1−100−2−21−25−290−100
Operating income−16−16−20−14−36−29−35−45−35−42−34−32
445889111111101010
Interest income445889111111341010
Other non-operating income0−4−5−8−8−9−11−11−11−10−10−10
Income before tax−12−12−15−6−28−20−24−34−24−32−24−22
Net income from continuing operations−12−12−15−6−28−20−24−34−24−32−24−22
Net income−12−12−15−6−28−20−24−34−24−32−24−22
EPS, basic−$0.25−$0.25−$0.30−$0.11−$0.51−$0.36−$0.38−$0.55−$0.39−$0.51−$0.39−$0.35
EPS, diluted−$0.25−$0.25−$0.30−$0.11−$0.51−$0.36−$0.38−$0.55−$0.39−$0.51−$0.39−$0.35
Weighted average shares, basic464749545557626262626363
Weighted average shares, diluted464749545557626262626363
EBITDA−15−11−14−5−28−20−23−33−24−31−24−22
Depreciation & amortization111111111100
EBIT−16−12−15−6−28−20−24−34−24−32−24−22